Where Did This Come From? The Origins of Modern Longevity Science
The serious scientific study of ageing has been underway for decades, but the current intensity of interest has specific origins. The publication of a landmark 2013 paper by López-Otín et al. in Cell — identifying nine "hallmarks of ageing" — gave the field a coherent biological framework for the first time. Rather than treating ageing as an inevitable, monolithic decline, this framework identified specific, measurable, and potentially modifiable cellular and molecular processes that drive the ageing phenotype.1
That conceptual shift — from ageing as destiny to ageing as biology — opened the door to intervention research in a way that had not previously been scientifically credible. By 2023, the hallmarks had been expanded to twelve, with the addition of disabled macroautophagy, chronic inflammation, and dysbiosis — bringing the framework into closer alignment with functional medicine's longstanding systems-biology model.2
In parallel, advances in genomics, proteomics, and metabolomics began to generate biological clocks — tools capable of estimating an individual's biological age independently of their chronological age. The most widely validated of these, the Horvath epigenetic clock (2013) and its subsequent iterations, made it theoretically possible to measure the pace of ageing in a living person and, critically, to test whether an intervention was slowing or reversing it.3
The combination of a biological framework, measurement tools, and a growing pool of venture capital from Silicon Valley created the conditions for a genuine scientific acceleration — alongside an equally genuine explosion of commercial hype that has made critical appraisal of this field more necessary than ever.
The longevity field encompasses serious peer-reviewed biological science conducted in leading academic institutions worldwide, and also a rapidly growing consumer wellness industry making claims that frequently exceed the evidence. These two things coexist and must be distinguished. This review focuses on the peer-reviewed science.
Lifespan vs. Healthspan: The Most Important Distinction in the Field
Before evaluating any longevity intervention, a fundamental distinction must be understood. Lifespan refers simply to the total duration of life. Healthspan refers to the period of life spent in good health — free from significant disease, disability, or functional impairment. These two things are not the same, and conflating them is one of the most common errors in both public and clinical discussions of longevity.
Current data suggests that in most developed nations, the gap between lifespan and healthspan is widening. People are living longer, but the final decade or more of many lives is spent managing multiple chronic conditions. The United Nations World Population Prospects (2024) projects the global population aged 65 and over will double from 761 million in 2021 to 1.6 billion within the next two to three decades.4 The economic and human cost of this extended morbidity is substantial.
The scientific consensus — and the functional medicine position — is that extending healthspan, not simply lifespan, is the clinically and ethically meaningful goal. This shifts the focus from life-extension as a technical achievement to the compression of morbidity: helping people remain biologically younger for longer, so that decline is compressed into a shorter period at the end of a longer, healthier life.
A 2024 study published in Nature Aging, tracking 108 individuals aged 25 to 75 using multi-omic profiling, found that biological ageing does not proceed as a linear, gradual decline. Instead, it occurs in two dramatic waves of molecular change — the first around age 40 and the second around age 60 — when proteins, metabolites, and gene expression patterns shift significantly. This has implications for when interventions may be most effective and suggests that the commonly held assumption of gradual, steady decline may be scientifically incorrect.5
The Twelve Hallmarks of Ageing: A Framework for Intervention
The hallmarks framework is not a list of symptoms of old age. It is a mechanistic map of the cellular and molecular processes that cause biological ageing. Understanding it is essential for evaluating any longevity intervention, because a credible intervention should be able to articulate which hallmark or hallmarks it targets, through what mechanism, and with what evidence.
The twelve hallmarks as of 2023 are: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, disabled macroautophagy, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, altered intercellular communication, chronic inflammation, and dysbiosis.2 The first five are classified as primary hallmarks — they cause damage directly. The next four are antagonistic — they represent beneficial processes in youth that become harmful with age. The final three are integrative — the downstream consequences of the upstream processes.
This architecture matters clinically. It explains why interventions targeting a single hallmark produce only modest effects in isolation — other ageing pathways remain active. A 2024 review in Aging by Panchin et al. examined combination intervention approaches in model organisms and found substantially larger lifespan and healthspan gains when multiple hallmarks were targeted simultaneously compared to single-target approaches.6 This is directly aligned with the functional medicine model, which has always argued that systems-based, multi-factorial interventions outperform single-variable approaches.
Is This a Fad? An Honest Assessment
The honest answer is that the longevity field contains both serious frontier science and a significant quantity of commercially motivated noise. Separating these requires attention to the evidence hierarchy.
The biological science of ageing — the hallmarks framework, epigenetic clocks, senescence biology, and the mechanistic study of interventions in model organisms — is unambiguously serious science, published in the highest-tier journals, conducted in major research universities, and increasingly funded by national health institutions. This is not a fad. It represents one of the most significant shifts in how biology conceptualises disease, given that ageing itself is the primary risk factor for the majority of chronic conditions.
What does have fad-like characteristics is the consumer longevity market — the proliferation of supplements, protocols, and clinics making claims about reversing biological age, extending lifespan, or "hacking" longevity that are either unvalidated in humans or extrapolated far beyond what the underlying research supports. A 2025 review in PMC on longevity interventions noted explicitly that "avoiding exaggerated claims is vital to prevent public disillusionment and uphold scientific integrity" and called for "a clear hierarchy of evidence prioritising randomised controlled trials over those based solely on molecular or preclinical indicators."7
The majority of longevity intervention research has been conducted in model organisms — yeast, nematodes, fruit flies, and mice. These findings are scientifically important and provide mechanistic insight, but the translation from model organism to human is frequently non-linear and often incomplete. Interventions that extend lifespan dramatically in C. elegans or mice have a poor track record of producing equivalent effects in humans. This is not a reason to dismiss the research — it is a reason to read it carefully and resist premature clinical extrapolation.
Key Interventions: What the Human Evidence Shows
Caloric Restriction and Time-Restricted Eating
Caloric restriction has the longest evidence base in longevity science, extending lifespan across virtually every model organism tested. The human evidence, however, is considerably more complex. The CALERIE trial — the most rigorous human caloric restriction study to date — found metabolic improvements and reductions in biological ageing markers at 25% caloric restriction, but long-term adherence was poor and the trial was not powered to assess lifespan outcomes.8
Time-restricted eating (TRE), which produces a caloric restriction effect through temporal limitation of eating windows, has a growing evidence base for metabolic health improvement, weight management, and inflammatory marker reduction. Its specific effects on biological ageing clocks in humans remain under investigation, but the mechanistic rationale — primarily through upregulation of autophagy — is well-supported.
Rapamycin and mTOR Inhibition
Rapamycin, originally developed as an immunosuppressant, has produced some of the most robust lifespan extension findings in mammalian models by inhibiting mTOR — a master regulator of cell growth and metabolism whose hyperactivity is implicated in multiple hallmarks of ageing. Its effects on lifespan in mice are among the most replicated findings in the field.
The human evidence, however, is where caution is warranted. A 2025 systematic review by Hands et al. from George Washington University, published in Aging, found that while some studies showed encouraging signs — improved immune responses and possible improvements in physical performance in older adults — no clinical trial has directly demonstrated that rapamycin extends lifespan or clearly slows the ageing process in healthy humans. A small study using the PhenoAge biological clock suggested users may have reduced their biological age by approximately four years, but this estimate was based on group averages rather than individual patient data and requires independent replication.9
Off-label rapamycin use in healthy adults is currently an experiment on human subjects with uncertain risk-benefit profile. The immunosuppressive effects of rapamycin are dose-dependent but real — and the optimal dosing protocol for longevity, if one exists, has not been established in humans.
Senolytics: Clearing Senescent Cells
Cellular senescence — the accumulation of damaged, non-dividing cells that release pro-inflammatory signalling molecules (the SASP, or senescence-associated secretory phenotype) — is one of the most robustly evidenced hallmarks of ageing. Senolytics are compounds that selectively clear senescent cells. The most studied combination is dasatinib and quercetin (D+Q).
In mouse models, senolytic treatment has improved physical function and extended both healthspan and lifespan. Early-phase human trials have shown that D+Q can reduce senescent cell burden in humans — an important proof-of-concept finding. However, no RCT has yet demonstrated clinically meaningful healthspan or lifespan benefits in humans, and the long-term safety profile of pharmaceutical senolytics in healthy people is unknown.10 Quercetin alone, as a supplement, does not deliver the same senolytic effects as the D+Q combination — a distinction worth making clearly when patients inquire.
NAD+ Precursors: NMN and NR
Nicotinamide adenine dinucleotide (NAD+) declines with age and plays a central role in mitochondrial function, DNA repair, and cellular signalling. Supplementation with precursors — nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR) — has attracted substantial commercial and scientific interest.
Human trials have demonstrated that NMN and NR supplementation safely and reliably raises NAD+ levels in blood and tissues. A 2023 review noted improvements in vascular function and inflammatory markers in some studies. However, whether raising NAD+ levels translates into meaningful healthspan benefits in humans remains unresolved. The commercial claims around NMN — particularly those relating to biological age reversal — substantially exceed the current evidence base.
GLP-1 Receptor Agonists and Longevity
Perhaps the most striking development in longevity medicine in 2025 is the repositioning of GLP-1 receptor agonists as potential gerotherapeutics. A November 2025 commentary in Nature Biotechnology argued that GLP-1s represent "the closest thing to what the longevity field has long sought in a gerotherapeutic" — one intervention, multiple organs improved, healthspan improved, and mortality risk reduced across large datasets.11
GLP-1s demonstrably target several hallmarks of ageing simultaneously: they reduce chronic inflammation, improve mitochondrial function, reduce cellular senescence markers, and act on deregulated nutrient-sensing pathways. Unlike rapamycin or senolytics, GLP-1s have vast human safety and efficacy data from their existing diabetes and obesity indications. The longevity application remains investigational, but this is a space where evidence may accumulate quickly.
Can Any Age Benefit? The Evidence Across the Lifespan
This is one of the most clinically relevant questions and one of the most honestly answered: the evidence strongly suggests that the foundations of longevity — lifestyle-based interventions targeting the hallmarks — are beneficial across the adult lifespan, but the optimal timing, type, and intensity of intervention likely differs by age.
The finding that biological ageing accelerates in two waves — around 40 and 60 — suggests that these may be periods of particular opportunity for targeted intervention. By contrast, the significant molecular changes that occur in the fourth decade of life suggest that waiting until symptoms appear to address ageing biology is likely suboptimal. This is the epidemiological argument for functional and preventive medicine that the longevity field makes with increasing biological precision.
For younger adults (under 40), the evidence most strongly supports lifestyle foundations: aerobic exercise (the most robustly evidenced intervention for biological ageing deceleration across all ages), resistance training, nutritional quality, sleep quantity and quality, stress management, and social connection. These are not less scientifically credible for being unglamorous — they target multiple hallmarks simultaneously with outstanding safety profiles and substantial human evidence.
For middle-aged adults, the same lifestyle foundations apply with greater urgency, and monitoring of biological age via available tools becomes increasingly clinically relevant. For older adults, evidence begins to emerge for pharmaceutical interventions in specific contexts — but these require medical supervision and should not be extrapolated from younger, healthier populations.
The functional medicine model — systems-based, root-cause, multi-factorial, personalised — is arguably the clinical framework most aligned with what longevity science is now demonstrating: that ageing is a multi-hallmark process requiring multi-system intervention. Practitioners who understand this framework are well-placed to guide patients through the noise of the longevity market with scientific credibility.
Where Is the Field Going?
The near-term trajectory of longevity science points in several directions simultaneously. Biological age clocks are improving rapidly in precision and accessibility; within a decade, measuring a patient's biological age through a blood test may be as routine as measuring cholesterol. The challenge will be linking biological age measurements to validated, actionable intervention protocols — a gap that remains significant.
Partial cellular reprogramming — reintroducing Yamanaka transcription factors to reset the epigenetic state of aged cells — has shown striking results in mouse models, with aged tissues displaying gene expression patterns characteristic of younger cells after treatment. A 2025 study found that seven months of periodic partial reprogramming in old mice produced significantly lower expression of ageing-associated genes in the kidney and liver. Human translation remains years away and the safety questions are substantial, but this represents the most radical potential advance in the field.
What seems clear is that longevity science has crossed from theoretical possibility to active, well-funded, scientifically serious pursuit. The question is no longer whether ageing biology can be modified — model organism data has established that it can — but whether those modifications translate to humans in meaningful, safe, and equitable ways. That question will not be resolved quickly, but its pursuit is shaping medicine in ways that practitioners need to understand now.
One of the underacknowledged challenges in longevity science is access. The interventions at the biological frontier — pharmaceutical senolytics, precision biological age testing, rapamycin protocols, advanced genetic therapies — are currently available only to those with significant financial resources. The most evidence-based longevity interventions — exercise, sleep, nutrition, stress management — are accessible to all. If longevity medicine develops as a premium service available only to the wealthy, the societal implications are serious and deserve active attention from the clinical community.
